← Back to Intel
Insider ActivityNRSN
Ben-Noon Alon, Chief Executive Officer at NeuroSense Therapeutics Ltd., bought $200K of NRSN
Updated Jun 19, 2026
Ben-Noon Alon
Chief Executive Officer
NeuroSense Therapeutics Ltd. ·
$NRSN
Transaction Details
| Insider | Ben-Noon Alon |
|---|---|
| Title | Chief Executive Officer |
| Company | NeuroSense Therapeutics Ltd. |
| Ticker | NRSN |
| Transaction Type | Purchase |
| Transaction Date | 2026-06-16 |
| Shares Traded | 250,000 |
| Price Per Share | $0.8 |
| Total Value | $200K |
| Filed Date | 2026-06-17 |
| Accession Number | 0001213900-26-069663 |
Ownership Context
| Shares Owned After Transaction | 4,534,233 |
|---|---|
| Ownership Type | Direct |
SEC Filing
Accession: 0001213900-26-069663
Other Insider Trades — NRSN
| Insider | Title | Action | Value | Date |
|---|---|---|---|---|
| Eisenberg Or | Chief Financial Officer | bought | $200K | 2026-06-16 |
| Binder Hagit | General Manager | traded | — | 2026-03-26 |
| Russek-Blum Niva | Chief Technology Officer | traded | — | 2026-03-26 |
| Eisenberg Or | Chief Financial Officer | traded | — | 2026-03-26 |
Full Ticker Profile
View all insider trades, dark pool activity, congressional filings, and the Whisper Score for NRSN — NeuroSense Therapeutics Ltd. →
Track NRSN insider activity in real time on The Wire →
Get alerts when Ben-Noon Alon files new trades — Go Pro →
Data sourced from SEC Form 4 insider trading filings. Transaction details are as reported to the Securities and Exchange Commission. This page does not constitute financial advice. StonkWhisper presents public records — it does not verify or guarantee the accuracy of SEC filings.
Last updated: June 19, 2026 at 07:00 UTC